'What gets measured gets fixed' and this is as true of the pharmaceutical industry as any other. The problem is that pharmaceutical businesses are complex. Drug research and development involves extended and expensive processes; defining appropriate metrics for these processes is not easy, yet ineffective or misguided metrics can be more damaging than none at all. David Zuckerman's Pharmaceutical Metrics is an extremely practical guide to selecting a system, selling it to top management, choosing and defining the right metrics for your system, communicating and displaying the results. And because metrics are about how to shape and develop your business, he explores how to deploy them organization-wide and make sure that they are driving business improvement. In order to reflect the needs of different types of pharmaceutical company the author uses four sample companies, throughout the book, to illustrate the principles for 'big pharma', 'micro pharma', a virtual development company and a CRO. This highly practical book provides a step-by-step guide to creating a state-of-the-art, strategy-driven metrics system for pharmaceutical R&D, supported by case studies of the techniques applied and tips for optimizing the system.
Table of Contents
Contents: The case for Metrics; Selecting a Metrics System; Creating the Foundation Using Strategy Maps; Developing Performance Metrics; Rounding out Your R & D Scorecard: Developing Financial, Customer and Organizational Growth Metrics; Metric Tips and Tricks; Displaying your Metrics; Closing the Strategy Loop. Index.
David S. Zuckerman is the world's foremost expert in the area of pharmaceutical R &D metrics, and lectures internationally on pharmaceutical metrics and balanced scorecards. He is owner and principal of Customized Improvement Strategies LLC - a management consulting firm that focuses on process improvement, organizational development, leadership development and change management; with clients that include large and small pharma R& D organizations, CROs and academic medical centers. Find out more about his work at www.rx-business.com
'This book's discussion of metrics and use of examples for the pharmaceutical industry is outstanding. The focus of this book may be the pharmaceutical industry, but the approach should be used in any business situation that measures and evaluates processes. I finally have a standard metrics reference for my team to utilize.' Timothy D. Hoos, Director, R&D Finance, Outsourcing, and Contracts 'This a book that should reside on the desk of everyone involved in Pharmaceutical R&D, a book that should not only be read but used as a reference guide by all senior staff.' Bill Taaffe, President Corporate Development, ICON Clinical Research A welcomed and needed addition to the field of drug development. David Zuckerman, a noted expert in this area brings a rigorous, quantitative, and disciplined approach to the planning and management of projects in the pharmaceutical industry. This is an important guide and resource for anyone working on bringing a drug product forward through R&D, registration, and commercialization.' Jeffrey W. Sherman, MD, FACP, Chief Medical Officer and Executive Vice President, NeoPharm, Inc. 'I read this book with great pleasure. It is concise and fun to read, particularly that the topic is a relatively abstractive one. People who read this book will realise that while it may not be difficult to compile a metrics report, it is a challenging job to do it right. As the environment requires us to develop new medicines efficiently and cost effectively, you will find this book a valuable resource for improving trial and drug development performance.' Gen Li, Ph.D., MBA, Head of Development Operations Productivity, PGRD Pfizer Inc. 'This practical and authoritative book will be essential reading for everyone directly involved with driving performance improvements within their organization, and a useful guide for others working in organizations that are not currently implementing (or are mis-implementing) performance improvement schemes.' Clinical Research Focus, May 2006